Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer

The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer transformed the care and prognosis of patients and heralded the era of ‘personalized medicine’ in thoracic oncology. Osimertinib, a third-generation EGFR inhibitor, has been established as...

Full description

Bibliographic Details
Main Authors:	Jiyun Lee, Zofia Piotrowska, Ross Soo, Byoung Chul Cho, Sun Min Lim
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-12-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359221144099

Similar Items

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
by: Juliann Chmielecki, et al.
Published: (2023-02-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
by: Ullas Batra, MD, DM, et al.
Published: (2021-01-01)

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC
by: Caterina De Rosa, et al.
Published: (2024-01-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
by: Dan Yan, et al.
Published: (2022-08-01)

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
by: Sally J. Adua, et al.
Published: (2022-12-01)

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
by: Takashi Higuchi, et al.
Published: (2019-04-01)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
by: Juliann Chmielecki, et al.
Published: (2023-06-01)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
by: Reina Hara, et al.
Published: (2021-05-01)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
by: Junjie GU, et al.
Published: (2021-11-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
by: Qiong Qin, et al.
Published: (2021-06-01)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018-10-01)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
by: Denis MG, et al.
Published: (2020-12-01)

Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib
by: Xiaohui Ren, et al.
Published: (2020-06-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
by: Ashwin Butle, et al.
Published: (2021-08-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022-04-01)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2022-10-01)

Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma
by: Yue A. Qi, et al.
Published: (2021-10-01)

Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
by: Elisa Bertoli, et al.
Published: (2022-06-01)

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
by: Takashi Higuchi, et al.
Published: (2020-10-01)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
by: Qiuyue Ye, et al.
Published: (2023-05-01)

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
by: Minehiko Inomata, et al.
Published: (2022-03-01)

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
by: Wen-Chien Huang, et al.
Published: (2021-11-01)

Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report
by: Hamid Mirshahidi, et al.
Published: (2023-09-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
by: Qiong Qin, et al.
Published: (2020-09-01)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
by: Alejandro Ríos-Hoyo, et al.
Published: (2022-04-01)

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
by: Keisuke Tabara, et al.
Published: (2012-01-01)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-06-01)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
by: Juliann Chmielecki, et al.
Published: (2023-02-01)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
by: Ken Uchibori, et al.
Published: (2017-03-01)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
by: Lin-Peng Zheng, et al.
Published: (2018-11-01)

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
by: Patricia L. Theard, et al.
Published: (2024-03-01)